Perfusia Biosciences aims to redefine the gold standard for preclinical models of human disease. A major and costly point of failure in the drug development pipeline is the inability of current preclinical models to accurately portray human physiology. As a result, many drugs tested in monolayer cell culture or animal models fail in clinical trials due to unforeseen complexities in human patients. To address this, we have developed VIVOS (Vascularized In Vitro Organ Systems), a proprietary microfluidic platform enabling vascular connection of stem cell derived 3D organ models. The core technology behind VIVOS allows for implantation and vascular support of various tissues within a microfluidic platform and can be used to model a wide range of organs and diseases from brain cancer to drug absorption in the gut.